Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Stroke. 2014 Jul;9(5):627-32. doi: 10.1111/ijs.12295. Epub 2014 Jun 2.

Management of acute stroke in patients taking novel oral anticoagulants.

Author information

1
School of Medicine and Pharmacology, The University of Western Australia, Perth, Western Australia, Australia.

Abstract

Each year, 1·0-2·0% of individuals with atrial fibrillation and 0·1-0·2% of those with venous thromboembolism who are receiving one of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) can be expected to experience an acute ischemic stroke. Additionally, 0·2-0·5% of individuals with atrial fibrillation who are receiving one of the novel oral anticoagulants can be expected to experience an intracranial hemorrhage. This opinion piece addresses the current literature and offers practical approaches to the management of patients receiving novel oral anticoagulants who present with an ischemic or hemorrhagic stroke. Specifically, we discuss the role of thrombolysis in anticoagulated patients with acute ischemic stroke and factors to consider concerning restarting anticoagulation after acute ischemic and hemorrhagic stroke.

KEYWORDS:

acute stroke; anticoagulants; intracerebral hemorrhage; secondary prevention; thrombolytic therapy

PMID:
24891030
PMCID:
PMC4149783
DOI:
10.1111/ijs.12295
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center